UAE Cough Hypersensitivity Syndrome Therapeutics Market Report 2022 to 2030

UAE Cough Hypersensitivity Syndrome Therapeutics Market Analysis

$ 3999

The UAE Cough Hypersensitivity Syndrome Therapeutics Market was valued at $41 Mn in 2022 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $69 Mn by 2030. The key drivers of this industry include the rising prevalence of Cough Hypersensitivity Syndrome, supportive government initiatives, and the development of novel therapeutics. The industry is primarily dominated by players such as Sanofi, Pfizer, Akorn, Novartis, Johnson & Johnson, and GSK among others.

ID: IN10AEPH316 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Riddhi Solanki

Buy Now

UAE Cough Hypersensitivity Syndrome Therapeutics Market Analysis Executive Summary

The UAE Cough Hypersensitivity Syndrome Therapeutics Market is at around $41 Mn in 2022 and is projected to reach $69 Mn in 2030, exhibiting a CAGR of 6.9% during the forecast period.

Cough Hypersensitivity Syndrome (CHS) is marked by an elevated propensity to cough in reaction to minimal stimuli like temperature variations, mechanical factors, or exposure to specific chemicals. Common underlying causes of CHS encompass conditions such as asthma, upper airway cough syndrome (UACS), gastroesophageal reflux disease (GERD), allergic or nonallergic rhinitis, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Risk factors include high susceptibility to cough-inducing stimuli such as citric acid or capsaicin. Available treatments are antitussive medications, inhaled corticosteroids (ICS), short-acting beta2-agonists (SABA), anticholinergics, antihistamines, P2X3 receptor antagonists, and neurokinin-1 receptor antagonists. Leading pharmaceutical companies like Johnson & Johnson, Bayer AG, Teva Canada Limited, GlaxoSmithKline plc, Pfizer, Novartis, and AstraZeneca produce CHS treatments.

Conditions such as COPD and chronic cough that can cause CHS affect a significant percentage of the UAE population. The market is propelled by major contributors such as the increasing prevalence of Cough Hypersensitivity Syndrome and subsequently its risk factors like smoking and pollution, the development of advanced therapeutics, and supportive government policies. However, conditions such as high costs of treatment, lack of human resources, and insufficient local research and development restrict the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Surge in prevalence of Cough Hypersensitivity Syndrome: UAE faces a considerable burden of conditions such as COPD and chronic cough affecting more than 3% and 5% of the population respectively. The awareness of CHS is increasing in the UAE, as both the general public and healthcare professionals are becoming more cognizant of the condition. This increased awareness can be attributed in part to enhanced diagnostic methods and expanded screening initiatives.

Development of novel therapeutics: Pharmaceutical companies are focusing on developing enhanced CHS treatments to increase efficacy and specificity. They are investigating novel therapeutic options, such as immunotherapy and neuromodulation which improve patient adherence, contributing to market growth.

Supportive government initiatives: The government prioritizes resources toward healthcare infrastructure, which includes specialist clinics focusing on respiratory disorders and implementation of national healthcare initiatives to increase access to CHS diagnosis and treatment.

Market Restraints

High treatment costs: Currently, available treatments for Cough Hypersensitivity Syndrome (CHS), such as corticosteroids and leukotriene receptor antagonists, are expensive, especially for patients requiring long-term therapy. This cost is a significant barrier for patients with limited financial resources and insurance cover

Workforce shortage: The shortage of pulmonologists, allergists, and other specialists with expertise in diagnosing and managing CHS can lead to delays in accessing timely and suitable care. Addressing this issue could involve making investments in the education and training of healthcare professionals in CHS, possibly through targeted scholarships or workshops, to mitigate the existing gap.

Inadequate research and development: In contrast to other respiratory conditions, CHS has a smaller patient population, making it less economically appealing for pharmaceutical firms to invest significantly in research and development. The specific mechanisms behind CHS are not fully understood, impeding the progress of more precise and efficient therapeutic advancements.

Healthcare Policies and Regulatory Landscape

The main regulatory body overseeing drugs and pharmaceuticals in the United Arab Emirates (UAE) is the Ministry of Health and Prevention (MOHAP). MOHAP is responsible for developing and implementing healthcare policies, regulating pharmaceuticals, and ensuring the safety and efficacy of drugs in the UAE.

Drug and pharmaceutical registration and licensure need extensive submissions to the MOHAP, which include details on the product's composition, manufacturing process, and clinical trial data. The regulatory authority evaluates these submissions to ensure conformity with international standards and once approved, provides distribution and sale licenses in the UAE.

New entrants in the regulatory framework of the UAE pharmaceutical sector must engage with the MOHAP to ensure compliance with regulatory requirements, documentation standards, and Good Manufacturing Practices (GMP).

Competitive Landscape

Key Players

Pfizer
GlaxoSmithKline
Boehringer Ingelheim
Bayer
F. Hoffman-La Roche Ltd
Sanofi
Novartis
Merck
Akorn
Johnson & Johnson

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Cough Hypersensitivity Syndrome Therapeutics Market Segmentation

By Drug Class

Antitussive Agents
Corticosteroids
Short Acting Beta-2 Agonists
Anti-cholinergic
Antihistamines
Proton Pump Inhibitors
Others

By Route of Administration

Oral
Inhalation
Others

By End Users

Hospitals
Speciality Clinics
Homecare

By Distribution Channel

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.